HRP20140570T1 - Pripravci i postupci za tretiranje friedreichove ataksije pomoä†u interferon game - Google Patents
Pripravci i postupci za tretiranje friedreichove ataksije pomoä†u interferon game Download PDFInfo
- Publication number
- HRP20140570T1 HRP20140570T1 HRP20140570AT HRP20140570T HRP20140570T1 HR P20140570 T1 HRP20140570 T1 HR P20140570T1 HR P20140570A T HRP20140570A T HR P20140570AT HR P20140570 T HRP20140570 T HR P20140570T HR P20140570 T1 HRP20140570 T1 HR P20140570T1
- Authority
- HR
- Croatia
- Prior art keywords
- interferon gamma
- use according
- ataxia
- cell
- friedreich
- Prior art date
Links
- 102000008070 Interferon-gamma Human genes 0.000 title claims 25
- 108010074328 Interferon-gamma Proteins 0.000 title claims 25
- 229960003130 interferon gamma Drugs 0.000 title claims 25
- 208000024412 Friedreich ataxia Diseases 0.000 title claims 6
- 238000000034 method Methods 0.000 title claims 4
- 239000000203 mixture Substances 0.000 title 1
- 102000003869 Frataxin Human genes 0.000 claims 4
- 108090000217 Frataxin Proteins 0.000 claims 4
- 102000009836 Aconitate hydratase Human genes 0.000 claims 3
- 108010009924 Aconitate hydratase Proteins 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 229940074404 sodium succinate Drugs 0.000 claims 2
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229960001855 mannitol Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 239000008223 sterile water Substances 0.000 claims 1
- 239000008227 sterile water for injection Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Claims (15)
1. Interferon gama za uporabu u postupku tretiranja Friedreichove ataksije.
2. Interferon gama za uporabu prema patentnom zahtjevu 1 koji se sastoji od ili sadrži barem 90% identičnosti sekvence prema bilo kojoj sekvenci iz Tablice 2.
3. Interferon gama za uporabu prema patentnom zahtjevu 1 pri čemu je spomenuti interferon gama rekombinantan.
4. Interferon gama za uporabu prema patentnom zahtjevu 1, pri čemu je spomenuti interferon gama ACTIIMMUNETM ili IMUKINTM.
5. Interferon gama za uporabu prema patentnom zahtjevu 1, koji se sastoji od ili sadrži SEQ ID NO:2.
6. Interferon gama za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5, pri čemu interferon gama povećava ekspresiju frataksina ili održava frataksin u stanici pacijenta koji ima Friedreichovu ataksiju.
7. Interferon gama za uporabu prema bilo kojem od patentnih zahtjeva 1 do 5, pri čemu interferon gama povećava aktivnost aconitaze u stanici pacijenta koji ima Friedreichovu ataksiju.
8. Interferon gama za uporabu prema patentnom zahtjevu 1, pri čemu se interferon gama primjenjuje u monomernom ili dimernom obliku, formuliran sa prikladnim ekscipijensom.
9. Interferon gama za uporabu prema patentnom zahtjevu 8 pri čemu se doza od 1-2 milijuna IU interferon game po m2 površine tijela ubrizgava potkožno ili intramuskularno, svaki drugi dan ili tri puta tjedno.
10. Interferon gama za uporabu prema patentnom zahtjevu 1 pri čemu se interferon gama primjenjuje u pripravku koji sadrži manitol, natrij sukcinat i polisorbat, te opcionalno sterilnu vodu.
11. Interferon gama za uporabu prema patentnom zahtjevu 1 pri čemu se interferon gama primjenjuje na pacijenta kroz injekciju.
12. Interferon gama za uporabu prema patentnom zahtjevu 1 pri čemu se pacijentu ubrizgava pripravak koji sadrži 100 mcg interferon game formuliranog u 20 mg manitola, 0.36 mg natrij sukcinata, 0.05 mg polisorbata 20 i sterilne vode za injektiranje.
13. Ex vivo postupak povećanja ekspresije frataksina u stanici koja ima nedostatnu količinu frataksina ili ima Friedreichovu ataksiju, koji sadrži primjenu efektivne količine interferon game na spomenutu stanicu.
14. Ex vivo postupak povećanja aktivnosti aconitaze u stanici koja ima nedostatnu količinu aktivnosti aconitaze ili ima Friedreichovu ataksiju, koji sadrži primjenu efektivne količine interferon game na spomenutu stanicu.
15. Ex vivo postupak prema patentnom zahtjevu 13 ili 14, pri čemu je interferon gama kao što je definirano u bilo kojem od patentnih zahtjeva 2 do 5.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37828410P | 2010-08-30 | 2010-08-30 | |
| PCT/IB2011/002710 WO2012028961A2 (en) | 2010-08-30 | 2011-08-30 | Compositions and methods for treating friedreich's ataxia with interferon gamma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140570T1 true HRP20140570T1 (hr) | 2014-07-18 |
Family
ID=45446093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140570AT HRP20140570T1 (hr) | 2010-08-30 | 2014-06-17 | Pripravci i postupci za tretiranje friedreichove ataksije pomoä†u interferon game |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8815230B2 (hr) |
| EP (1) | EP2611457B1 (hr) |
| CA (1) | CA2809747C (hr) |
| DK (1) | DK2611457T3 (hr) |
| ES (1) | ES2466765T3 (hr) |
| HR (1) | HRP20140570T1 (hr) |
| PL (1) | PL2611457T3 (hr) |
| PT (1) | PT2611457E (hr) |
| SI (1) | SI2611457T1 (hr) |
| SM (1) | SMT201400111B (hr) |
| WO (1) | WO2012028961A2 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015023941A1 (en) | 2013-08-16 | 2015-02-19 | Rana Therapeutics, Inc. | Oligonucleotides targeting euchromatin regions of genes |
| WO2015023939A1 (en) * | 2013-08-16 | 2015-02-19 | Rana Therapeutics, Inc. | Compositions and methods for modulating expression of frataxin |
| US10442779B2 (en) | 2014-09-22 | 2019-10-15 | Fratagene Therapeutics S.R.L. | Compositions and methods for treating Friedreich's ataxia |
| WO2016103223A1 (en) | 2014-12-23 | 2016-06-30 | Fratagene Therapeutics Ltd. | Methods of treating friedreich's ataxia using src inhibitors |
| US10758558B2 (en) | 2015-02-13 | 2020-09-01 | Translate Bio Ma, Inc. | Hybrid oligonucleotides and uses thereof |
| US11237299B2 (en) | 2017-05-01 | 2022-02-01 | I.M. Systems Group, Inc. | Self-learning nowcast system for modeling, recording, and predicting convective weather |
| US10426775B2 (en) | 2017-09-11 | 2019-10-01 | Fratagene Therapeutics Srl | Methods for treating Friedreich's ataxia with etravirine |
| AU2019313339A1 (en) * | 2018-07-30 | 2021-03-11 | The Board Of Trustees Of The Leland Stanford Junior University | Interferon-gamma biased agonists |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1378753B1 (en) * | 2002-07-01 | 2006-05-31 | Santhera Pharmaceuticals (Schweiz) GmbH | A screening method and compounds for treating Friedreich Ataxia |
| UA95099C2 (ru) | 2006-02-22 | 2011-07-11 | Арнольд Мунних | Применение деферипрона при лечении железо-индуцированного повреждения митохондрий, который является следствием атаксии фридрейха |
-
2011
- 2011-08-30 DK DK11805174.7T patent/DK2611457T3/da active
- 2011-08-30 US US13/820,092 patent/US8815230B2/en active Active
- 2011-08-30 CA CA2809747A patent/CA2809747C/en not_active Expired - Fee Related
- 2011-08-30 ES ES11805174.7T patent/ES2466765T3/es active Active
- 2011-08-30 WO PCT/IB2011/002710 patent/WO2012028961A2/en active Application Filing
- 2011-08-30 EP EP11805174.7A patent/EP2611457B1/en active Active
- 2011-08-30 PL PL11805174T patent/PL2611457T3/pl unknown
- 2011-08-30 SI SI201130188T patent/SI2611457T1/sl unknown
- 2011-08-30 PT PT118051747T patent/PT2611457E/pt unknown
-
2014
- 2014-06-17 HR HRP20140570AT patent/HRP20140570T1/hr unknown
- 2014-08-14 SM SM201400111T patent/SMT201400111B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8815230B2 (en) | 2014-08-26 |
| CA2809747C (en) | 2018-05-01 |
| SI2611457T1 (sl) | 2014-09-30 |
| PL2611457T3 (pl) | 2014-11-28 |
| EP2611457B1 (en) | 2014-03-19 |
| CA2809747A1 (en) | 2012-03-08 |
| ES2466765T3 (es) | 2014-06-11 |
| SMT201400111B (it) | 2014-09-08 |
| EP2611457A2 (en) | 2013-07-10 |
| WO2012028961A2 (en) | 2012-03-08 |
| PT2611457E (pt) | 2014-06-05 |
| DK2611457T3 (da) | 2014-05-12 |
| US20130156734A1 (en) | 2013-06-20 |
| WO2012028961A3 (en) | 2012-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140570T1 (hr) | Pripravci i postupci za tretiranje friedreichove ataksije pomoä†u interferon game | |
| BR112014012739A2 (pt) | composições e métodos para o tratamento do vírus da hepatite c | |
| HRP20220718T1 (hr) | Kombinacijska terapija uključujući inhibitor mdm2 i jedan ili više dodatnih farmaceutski aktivnih sredstava za liječenje raka | |
| US20160263191A1 (en) | Combination Treatments and Compositions for Wound Healing | |
| HRP20170056T2 (hr) | Terapija male učestalosti glatiramer acetatom | |
| RU2020111236A (ru) | Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности | |
| DOP2014000067A (es) | Tratamiento combinado (por ejemplo con abt-072 o abt-333) de agentes antivirales de acción directa (daas) para uso en el tratamiento de hcv | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| BR112013027674A2 (pt) | "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha". | |
| HRP20160646T1 (hr) | Poboljšano liječenje multiplog mijeloma | |
| NZ707377A (en) | Combination therapy methods for treating proliferative diseases | |
| HRP20220068T1 (hr) | Staphylococcus aureus leukocidini, terapijski pripravci, i njihova uporaba | |
| NZ631155A (en) | Combination of two antivirals for treating hepatitis c | |
| JP2014530873A5 (hr) | ||
| RU2013148779A (ru) | Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени | |
| MX2015012536A (es) | Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc. | |
| RU2015116264A (ru) | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом | |
| AR093185A1 (es) | Virus prrs (sindrome reproductivo y respiratorio porcino) que induce al interferon tipo i en celulas susceptibles | |
| AR112166A1 (es) | Composiciones terapéuticas y métodos para el tratamiento de hepatitis b | |
| IN2014DN06920A (hr) | ||
| HRP20180221T1 (hr) | Novi sustav prijenosa lijeka zasnovan za jcv-vlp | |
| MX2015007402A (es) | Fusion de hormona de crecimiento humano y albumina, formulacion y usos de los mismos. | |
| HRP20170880T1 (hr) | Sastavi za brtvljenje | |
| JP2018512874A5 (hr) | ||
| Hasegawa et al. | Intracoronary injection of granulocyte colony-stimulating factor ameliorates the progression of left ventricular remodeling after myocardial ischemia/reperfusion in rabbits |